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Fahr’s disease or Fahr’s syndrome is a rare, neurological disorder characterized by abnormal calcified deposits in
basal ganglia and cerebral cortex. Calcified deposits are made up of calcium carbonate and calcium phosphate, and
are commonly located in the Basal Ganglia, Thalamus, Hippocampus, Cerebral cortex, Cerebellar Subcortical white
matter and Dentate Nucleus. Molecular genetics of this disease haven’t been studied extensively; hence evidence at
the molecular and genetic level is limited. Fahr’s disease commonly affects young to middle aged adults. Etiology
of this syndrome does not identify a specific agent but associations with a number of conditions have been noted;
most common of which are endocrine disorders, mitochondrial myopathies, dermatological abnormalities and
infectious diseases. Clinical manifestations of this disease incorporate a wide variety of symptoms, ranging from
neurological symptoms of extrapyramidal system to neuropsychiatric abnormalities of memory and concentration
to movement disorders including Parkinsonism, chorea and tremors amongst others. Diagnostic criteria for this
disease has been formulated after modifications from previous evidence and can be stated briefly, it consist of
bilateral calcification of basal ganglia, progressive neurologic dysfunction, absence of biochemical abnormalities,
absence of an infectious, traumatic or toxic cause and a significant family history. Imaging modalities for the
diagnosis include CT, MRI, and plain radiography of skull. Other investigations include blood and urine testing for
hematologic and biochemical indices. Disease is as yet incurable but management and treatment strategies mainly
focus on symptomatic relief and eradication of causative factors; however certain evidence is present to suggest
that early diagnosis and treatment can reverse the calcification process leading to complete recovery of mental
functions. Families with a known history of Fahr’s disease should be counseled prior to conception so that the birth
of affected babies can be prevented. This review was written with the aim to remark on the current substantial
evidence surrounding this disease.Definition
Basal ganglia calcification is also known as Fahr’s disease
or Fahr’s syndrome. It is a rare inherited or sporadic
neurological disorder with a prevalence of <1/1,000,000
[1-3]. It was first described by German neurologist Karl
Theodor Fahr in 1930 [4].It is characterized by abnormal
deposition of calcium in areas of the brain that control
movements including basal ganglia, thalamus, dentate
nucleus, cerebral cortex, cerebellum, subcortical white
matter, and hippocampus [5].Most cases present with
extra pyramidal symptoms initially. Additionally, they* Correspondence: coolaslam8@hotmail.com
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reproduction in any medium, provided the ormay present with cerebellar dysfunction, speech diffi-
culty, dementia and neuropsychiatric symptoms [6].Molecular genetics
Fahr’s disease is most commonly transmitted as an
Autosomal Dominant trait; but it may also be passed on
as an autosomal recessive trait or it may occur sporadic-
ally [1,7]. A Locus at 14q (IBGC1) has been suggested to
be involved commonly. A second locus has been identi-
fied on chromosome 8 and a third on chromosome 2
[8-10]. A loss of function mutation in the gene encoding
type III sodium dependent phosphate transporter 2
(SLC20A2) located on chromosome 8 has also been
reported as the molecular level to form the genetic basis
for the pathophysiology of this disease [11-13].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Fahr’s syndrome typically affects individuals in the 3rd
and 4th decades of their lives [2,14].
Diagnostic criteria
Diagnostic criteria of Fahr’s syndrome has been modified
and derived from Moskowitz et al. 1971, Ellie et al. 1989,
Manyam 2005 [3,15,16] and it can be stated as follows:
 Bilateral calcification of the basal ganglia visualized
on neuroimaging. Other brain regions may also be
observed.
 Progressive neurologic dysfunction, which generally
includes a movement disorder and/or
neuropsychiatric manifestations. Age of onset is
typically in the fourth or fifth decade, although this
dysfunction may also present in childhood.*
 Absence of biochemical abnormalities and somatic
features suggestive of a mitochondrial or metabolic
disease or other systemic disorder.
 Absence of an infectious, toxic, or traumatic cause.
 Family history consistent with autosomal dominant
inheritance.
Synonyms
Fahr’s disease, Fahr’s syndrome, idiopathic basal ganglia





Symmetrical calcification of the basal ganglia occurs in a
variety of familial and non-familial conditions; hence it
doesn’t necessarily direct us towards a definitive diagno-
sis of Fahr’s syndrome.
 Congenital or early onset finding along with
intellectual disability or presence of systemic
involvement should alert one to the possibility of
alternative diagnosis.
 When latent Tetany and myopathic changes occur
with changes in somatosensory, visual and brain
stem auditory responses, then parathyroid
dysfunction, mitochondrial disease or other disease
associated with brain calcification may be
considered.
 Basal ganglia calcification, discovered in infancy
along with ophthalmologic abnormality should
prompt the consideration of infectious disease [17].
 It is differentiated from calcified angiomas,
infections, enchapalitides and Addision’s disease by
its severity and characteristic distribution.Methodology
Available literature concerning Fahr syndrome was ana-
lyzed. Literature search was conducted by using the fol-
lowing databases: Pub med, Google Scholar and Google.
Key words used for searching were Fahr syndrome, Fahr
disease and bilateral basal ganglia calcification. Using the
word “Fahr’s syndrome” in Pub med, 64 articles were
found from 1954–2013, term “Fahr’s disease” turned up
218 articles from 1951–2013 and the word “bilateral basal
ganglia calcification” unearthed 172 articles from 1951–
2013. Clinical data and diagnostic information was col-
lected from abstracts or full text articles. Only articles
written in the English language and case reports which
had a definitive diagnosis of Fahr syndrome were included.
Articles irrelevant to our study objectives were excluded.Diagnostic methods
Computed tomography
It is the preferable method of localizing and assessing the
extent of Cerebral Calcification. Most frequently affected
area is the lenticular nucleus, especially the internal globus
pallidus while Cerebellar gyri, brain stem, centrum
semiovale, and subcortical white matter may also affected.
Calcifications in the putamen, thalami, caudate, and den-
tate nuclei are also common. Occasionally, calcium de-
posits begin or predominate in regions outside the basal
ganglia. Calcification seems to be progressive and gradual.MRI (magnetic resonance imaging)
Calcified areas in basal ganglia give a low intensity signal
on a T2 image and low or high intensity signals on a T1
weighted plane [18]. The cerebellar lesions are found to
be more heterogeneous. There may be a chance of high
intensity signals in both T1 and T2 images due to reactive
gliosis or degenerating tissue within calcified areas [17,19].Plain skull radiograph
The plain skull radiograph has been shown to be the im-
aging modality of diagnostic value. Calcifications appear
as clusters of punctate densities symmetrically distributed
above Sella Turica and lateral to the midline, while sub-
cortical and cerebellar calcifications appear wavy [17].Testing strategy for primary familial basal
calcification
Proband
Definitive diagnosis of primary familial basal calcification
is established by Proband. For individuals in whom a
diagnosis of Primary familial basal calcification is being
considered, other causes of brain calcification should be
eliminated prior to pursuing genetic testing. Such evalu-
ations are as follows:
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of calcium metabolism and heavy metal intoxication
 Cerebrospinal fluid analysis to assess for an
infectious etiology and autoimmune disease.
If no other primary cause for brain calcification is
detected or if the family history is suggestive of autosomal
dominant inheritance, molecular genetic testing should be
considered.
Sequencing of SLC20A2 should be undertaken first. If
no mutation is identified, deletion/duplication analysis
of SLC20A2 can be deliberated.
If no identifiable mutation or deletion in SLC20A2 is
found, consider sequence analysis of PDGFRB.
If molecular genetic testing of both SLC20A2 and
PDGFRB does not identify a disease causing mutation or
deletion, consider other genetic diseases associated with
brain calcifications.
Predictive testing for at-risk asymptomatic adult family
members may include brain CT scan to evaluate calcium
deposits. Presence of calcium deposits in this situation
may be predictive of disease even in the absence of an
identifiable familial mutation. In at-risk asymptomatic
adult family members without brain calcifications, predict-
ive testing requires prior identification of the disease-
causing mutation in the family. Prenatal diagnosis and pre-
implantation genetic diagnosis (PGD) for at-risk pregnan-
cies require prior identification of the disease-causing
mutation in the family [17].
Other baseline testing
In Fahr’s syndrome, certain hematological and biochem-
ical investigations need to be carry out.
 Serum concentrations of calcium, phosphorus,
magnesium, alkaline phosphatase, calcitonin and PTH
should be tested.
 The Elisworth Howard test, yielding a 10–20 fold
increase in urinary cAMP excretion following
stimulation with 200 μmoles of parathyroid
hormone aids in diagnosis.
 CSF evaluation of bacteria, viruses and parasite
should be conducted
 Levels of ALP, urinary cAMP, serum creatinine,
osteocalcin, serum lactic acid at rest and after exercise
should be obtained. There is also an indication to
measure the levels of 1,25 hydroxy Vit D3 [20,21].
 Natural Killer cells (NK) should be assessed in all
suspected cases of Fahr’s syndrome as they were
found to be raised in patients of Fahr’s syndrome [22].
Epidemiology
To this date, very few studies have determined the fre-
quency of basal ganglia calcification. In one study, 7040patients were examined with CT scans, out of which 72
(10.02%) showed symmetrical intracranial calcifications [23].
In a prospective study, calcification was detected in 30 out
of 1478 (2%) patients on CT scans [24]. In another study, a
review of 6,348 CT scans took place, out of which 39
(0.49%) confirmed the diagnosis of Fahr’s syndrome [25].
Pathogenesis
Pathological features, being similar in both adults and in-
fants, are not affected by age. At the molecular level, calci-
fication generally develops within the vessel wall and in
the perivascular space, ultimately extending to the neuron.
Due to defective iron transport and free radical produc-
tion, tissue damage occurs which leads to the initiation of
calcification. It occurs secondarily around a Nidus com-
posed of mucopolysaccharide and related substances. Pro-
gressive basal ganglia mineralization tends to compress
the vessel lumen, thus initiating a cycle of impaired blood
flow, neural tissue injury and mineral deposition. Basal
ganglia concretions are recognized as basophilic globules
tracking the vessels of arteries, veins and capillaries. Elec-
tron microscopy also shows the evidence of connection
between spherical and hemispherical bodies formed in the
adventitia of blood vessel and surrounding glial cells while
intima is usually preserved. Microscopy reveals perivascu-
lar granules lying in the region above midbrain. The Lat-
eral Pallidum is found to be more calcified relative to the
Medial Pallidum. However, in another study, researchers
found a sub-group with isolated calcification confined to
Medial Pallidum [23,26]. Mineral composition of the calci-
fications varies with anatomical site and their proximity to
vasculature calcifications. It may be due to the abnormal
metabolism of calcium and phosphorus while some re-
ports tend to contradict this finding [18,27,28]. In a review
of 4219 CT scans, it was deduced that most calcifications
occur bilaterally and symmetrically while a few occur uni-
laterally and there was no abnormality in metabolism of
calcium, denying the pathophysiologic significance of con-
current altered calcium metabolism [29]. Calcifications
commonly occur in basal ganglia, thalamus, dentate nu-
cleus, cerebral cortex, cerebellum subcortical white mat-
ter, and hippocampus [14,18]. Deposits are composed of
mineral compounds like calcium phosphate and carbon-
ate; glyconate, mucopolysacchride and metals including
Iron, Copper, Magnesium, Zinc, Aluminum, Silver and
Cobalt may also be found [30-32].
Etiology of Fahr’s syndrome
Endocrine disorder
Endocrine disorders, particularly parathyroid distur-
bances are most commonly associated with Fahr’s
syndrome. These abnormalities include idiopathic hypo-
parathyroidism, secondary hypoparathyroidism, pseudohy-
poparathyroidism, pseudo-pseudohypoparathyroidism and
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uncommon condition characterized by the absence, fatty
replacement or atrophy of the parathyroid glands. Second-
ary Hypoparathyrodism occur post-thyroidectomy as a
complication of surgery. Pseudohypoparathyroidism is a
condition associated primarily with resistance to the para-
thyroid hormone and the term Pseudopseudohypo-
parathyroidism is used to describe a condition where the
individual has the phenotypic appearance of Pseudohypo-
parathyroidism type 1a, but is biochemically normal
[17,24,33-35]. In a literature review of 150 cases, it was
found that 35(23.3%) had idiopathic hypoparathyrodism
whereas 23 (15.3%) had post thyroidectomy or secondary
hypoparathyrodism [36,37]. Reduced parathormone (in
hypoparathyrodism) or reduced renal response to para-
thormone (pseudohypoparathyroidism) causes hyperpho-
sphatemia and hypocalcaemia, which in turn promotes
calcification. In another study, it was found that Fahr’s syn-
drome occurred in 20(21.5%) of 93 patients with idiopathic
hypoparathyrodism and 26(42.6%) of 61 patients with
pseudo hypoparathyrodism [30,38]. Hypoparathyrodism is
either primary or secondary and usually presents in first
six decades of life and can be clinically recognized by Cata-
ract, Tetany, Seizures, Dysarthria, increased Intracranial
Pressure, Papilledema, soft tissue calcification, Congestive
Heart failure, Pernicious anemia, dry hair, Alopecia, dental
dysplasia, carries and predisposition to Moniliases [17,24].
In a recent case report, results of the histopathological
examination revealed that there were five types of calcium
deposits within the walls of capillaries and small and
medium-sized arteries from the intracerebral affected
areas. The histopathology specimen of the thyroid and
parathyroid gland showed chronic lymphocytic thyroiditis
and fibro-adipose tissue respectively. The symmetrical in-
tracerebral calcifications were consequential of the
hypoparathyrodism [39].
Pseudo and Pseudo-pseudohypoparathyroidism are de-
picted by a phenotypic spectrum caused by mutations in
RNA and they also tend to occur in the same family.
Average age of onset of PHP is at eight to ten years, and its
clinical manifestations are similar with hypoparathyrodism
except that intellectual disability is slightly more common
in pseudohypoparathyroidism. Affected individuals have
features of Albright Osteodystrophy. In Pseudopseudo-
hypoparathyroidism, patients exhibit similar features but
they do not have any biochemical abnormality, as opposed
to patients of Pseudohypoparathyroidism. The serum con-
centrations of calcium and phosphorus are normal and
there is a normal response to PTH secretion [17,40].
Kenny Caffey syndrome type 1
Fahr’s syndrome has been known to be associated with the
Kenny Caffey Syndrome Type 1. Being caused by a muta-
tion in the TBCE gene, this syndrome is characterized bythe symptoms of growth delay, cortical thickening of long
bones, hypocalcaemia, hypothyroidism, and calcification of
basal ganglia [41].Vitamin disorder
Vitamin D is a known player in the process of calcium
metabolism due to which a disturbance in its homeosta-
sis has significant implications for patients with Fahr’s
syndrome [24].Mitochondrial myopathy
Due to the association of mitochondrial myopathy with
abnormality in Calcium metabolism and increment in
serum lactic acid and CSF protein, it was predicted that
Fahr syndrome is also associated with Myopathies. One
of these, the Kearn- Sayre syndrome, which consists of
the triad of external opthalmoplegia, pigmentary retinal
degeneration and increased CSF protein, has also been
found to be associated with Fahr syndrome. In a study
of 24 subjects from six kindreds with MELAS (myop-
athy, encephalopathy, lactoacidosis and stroke like syn-
drome), results revealed that bilateral basal ganglia
calcification is the commonest radiological finding in
mitochondrial disease [42,43].Adult onset neurodegenarative conditions
Neurodegeneration with brain iron accumulation disease
(NBIA)
It is a form of NBIA and it presents with dystonia which is
progressive, basal ganglia calcification dysarthria, rigidity
and pigmentary retinopathy [17].Neuroferritinopathy
It is also a form of NBIA and it typically manifests as adult
onset chorea, dystonia and subtle cognitive defect along
with excess iron storage or cystic degeneration in the Pu-
tamen [17].Polycystic lipomembrenous osteodysplasia with sclerosing
leukoencephalopathy
It is characterized by fractures resulting from polycystic
osseous lesion, frontal lobe syndrome and progressive se-
nile dementia beginning in the 4th decade while bilateral
calcifications are visualized on CT imaging [17].Dermatological disorders
Bilateral basal ganglia calcifications are correlated with a
dermatological lesion, namely, lipoid protienosis which
reveals itself with the observable conditions of seizures,
dementia, hyalonisis of skin and mucous membrane, alo-
pecia, photosensitivity and dwarfism [30].
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Intrauterine or perinatal
Infections by Toxoplasmosis, rubella, CMV, herpes may
result in calcifications of basal ganglia and dentate nu-
cleus [17].
Inherited congenital or early onset syndromes
Cockayne syndrome
CS TYPE I
It comprises of developmental delay, hearing and visual
loss, CNS and PNS disabilities along with Intracranial
calcification of basal ganglia [17,35].
CS TYPE II
It is a more severe form of the Cockayne Syndrome,
known as “Congenital Cockayne Syndrome, Cerebro-
Occulofascial syndrome or Pena Shokeir type II syn-
drome. It consists of growth failure with little or none
post natal neurologic development, congenital cataract,
eye anomalies, kyphosis and joint contracture [17,35].
Aicardi-Goutières syndrome
It is an early onset encephalopathy characterized by phys-
ical and mental handicap with calcification of basal gan-
glia, particularly Putamen, Globus Pallidus and thalamus,
leukodystrophy, cerebral atrophy, CSF leukocytosis, in-
creased concentration of interferon alpha in CSF, progres-
sive microcephaly, irritability, feeding problems, sterile
pyrexia, and in 20-25% of individuals by generalized tonic
clonic seizures [17].
Tuberous sclerosis complex
It is a disorder affecting multiple systems including
abnormalities of skin (Hypermelanotic, Macules, Fascial
Angiofibromas, Shagreen Patches, Fibrous Fascial
Plaques, Ungual Fibroma), brain (Cortical Tubers,
Subependymal Nodules, seizures, Intellectual disabil-
ity/development delay), kidney (Angiolipoma, cysts)
and heart (rhabdomyoma and arrhythmia). Cerebral
hamartomas may be calcified and they are mainly peri-
ventricular or subcortical [17].
Brucellosis
In a study, 65 cases of brucellosis were studied, of which
9(13.8%) were shown to have CT detected basal ganglia
calcification. Out of these, 5 had meningitis and 4 had
psychiatric manifestations. Calcification was unilateral in
3 cases, bilateral and symmetric in 4 cases and bilateral
but asymmetric in 2 [44].
Coat’s disease
A case report of a patient with bilateral basal ganglia
calcification was successful in providing evidence thatcoat’s disease is associated with bilateral basal ganglia
calcification [45].
Normal aging
Calcification of the basal ganglia is an incidental finding
in about 0.3%-1.5% of brain CT scans, especially in eld-
erly individuals (age therefore being the most common
cause). Microscopic calcifications can be observed in the
Globus Pallidus and dentate nucleus in up to 70% of aut-
opsy series. These calcifications are generally confined to
the Globus Pallidus and do not have associated clinical
findings [46,47].
All etiological factors were combined in Table 1
Clinical features
Neurological features
A variety of neurological signs and symptoms are associ-
ated with Fahr’s syndrome. In adults loss of consciousness
and seizures have been reported with hypothyroid hypocal-
caemia [48,49]. Tetany is present, but it is difficult to dis-
tinguish from occasional myoclonus of epileptic disorder.
Also, spasticity, gait disorder, speech impairment, demen-
tia, parkinsonism, chorea, tremors, dystonia, myoclonus
and coma are present. Papilledema of intracranial hyper-
tension, Pleocytosis of CSF, paroxysmal Choreothetosis
and paroxysmal dystonic Choreoathetosis have also been
reported [50].
In a survey of 72 patients with intracranial calcifications,
Kazis reported that extrapyramidal symptoms were present
in 15(20.8%) patients, while in another study the frequency
of extrapyramidal symptoms was calculated to be 56%
[23,25]. In a research conducted on 982 people of rural
Bavarian origin, 1(5.9%) of 17 Parkinsonism subjects had
Fahr’s syndrome. Neurological manifestations may be con-
fined to one side of the body despite the presence of bilat-
eral calcifications [51,52].
Konig reported that one half of Fahr’s syndrome pa-
tients have neurological symptoms, while another study
by Kazis reported a figure of 33.3% that is, one thirds of
the patients were found to have them [23,25].
These statistics suggest that the prevalence of neuro-
logical symptoms may vary in FS. It has been suggested
that extent or side of the lesion have an effect on manifest-
ation but when it comes to dementia and extrapyramidal
symptoms, they become worse with more extensive calcifi-
cation [53]. Clinical findings may correlate with site of cal-
cification as Lopes-Villega reported that out of 18 Fahr’s
syndrome patients, 2(11.1%) had parkinsonism (with
Pallidal thalamic and Cerebellal dentate calcification), 4
(22.2%) had transient ischemic attacks ( Pallidal and Puta-
men calcification), 1(5.6%) had dysarthria and orthostatic
hypotension (caudate and putamen calcification). Lesions
were reported to be located in Globus Pallidus in 16
Table 1 Etiological manifestations of Fahr’s syndrome
S.No Etiologies














3 Infectious disease Intrauterine and Perinatal infections
Cockayne Syndrome Type 1
Cockayne syndrome Type 2
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in 1(5.6%) and cerebellar dentate nucleus in 1(5.6%) out of
18 patients [54].
Movement disorder
Movement disorders in Fahr syndrome unveil as a
spectrum of symptoms including clumsiness, fatigability,
unsteady gait, slow or slurred speech, dysarthria dysphagia,
involuntary movements and muscle cramping [16,27,55,56].
Neurological evaluation reveals that parkinsonism is
present in 57%, chorea 19%, tremors 8%, dystonia 8%, athe-
tosis 5% and orofacial dyskinesia in 3% of patients [2].
Neuropsychiatric symptoms
These range from mild difficulty with concentration and
memory to changes in personality or behaviors to psych-
osis and dementia [8,28]. A rare form of frontotemporal
dementia with neurofibrillary tangles and Fahr’s type cal-
cification was observed in a 50 year old Japanese woman
who showed up with progressive dementia but neither
extrapyrimidal symptoms nor metabolic disorder were
observed [57]. Three cases with unusual type of pre-
senile dementia were studied; calcareous deposition of
Fahr’s type was present in each of them. Signs and symp-
toms were established to be neither those of Alzheimer
nor those of Pick’s disease [58]. Patients with extensive
calcification don’t seem to have a higher proportion of
neurological impairment (35.8%) relative to those whoshow limited calcifications (34.5), but patients with extensive
calcification did exhibit a higher frequency of psychiatric dis-
orders (50%) than limited ones (34.5%). In another case, a
50 year old female patient with unimpaired basic and higher
motor function had grossly compromised memory and at-
tentional function but she remained neurologically asymp-
tomatic. Neuropsychiatric illness may be present in the form
of Schizophrenia like Psychosis, Dementia, Depression,
Apoplexia, Deterioration of intelligence, inability to make
decisions and effective organic alterations [28,53,59-62]. In
one case report it was reported that reduced glucose uptake
in PET scan was not only confined to the Putamen and
Globus Pallidus, but extended to involve the temporal and
parietal cortices, bilaterally. These functional changes may
correspond to the neuropsychological deficits observed, i.e.
disturbed selective attention and cognitive flexibility, verbal
perseverations, and declarative memory deficits. It has been
demonstrated that functional changes may precede cerebral
atrophy in Fahr's syndrome and may reflect deficits in func-
tional circuits, which involve both the basal ganglia and the
frontal, parietal, and temporal lobes [63]. Lam et al. de-
scribed two cases of Fahr’s syndrome with frontal lobe
symptoms. One of them initially developed frequent uncon-
trollable bursts of laughter and crying and later, dysarthric
speech while the second patient presented with progressive
changes in personality and behavior [64].
All clinical features were combined in Table 2
Management of Fahr’s syndrome
To this date, various treatments have been administered to
Fahr’s patients in an attempt to achieve remission or at
least stabilization. Several approaches based on diverse bio-
logical theories and small scale clinical experiences have
been proposed. Pharmacological treatment should be used
to improve anxiety, depression, and obsessive compulsive
disorder and to alleviate dystonia. Oxybutynin is used for
urinary incontinence and antiepileptics are used for sei-
zures [17]. Early diagnosis and treatment of the cause may
abate the calcification process as described in a case in
which treatment of hypoparathyrodism led to reversal of
mental retardation in a 3 year old [65]. Seizures and move-
ment disorders in Fahr’s syndrome which are related to the
parathyroid disorder can be resolved with the correction of
phosphate and calcium levels for e.g. treatment with alpha
hydroxy vitamin D3 and corticosteroids reversed neuro-
logical deficits [52,66]. Clonazepam and atypical anti-
psychotic also offer a distinct advantage in treating patients
with Fahr’s syndrome [24].
Great caution is indicated when using Lithium because it
can further increase the risk of seizures in patients with
Fahr’s syndrome. Treatment strategies involving the use of
Carbamazepine, Benzipenes and Barbiturates may exacer-
bate underlying gait disorders [24].
Table 2 Clinical features of Fahr’s syndrome
S. No Clinical features
























Inability to make decisions
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Optimal time for determination of genetic risk is before
pregnancy.
Testing of at risk asymptomatic adult
Brain CT scan serves as a pre-symptomatic test in at risk
individual but its not useful for predicting age of onset,
severity, type of symptoms or rate of progression in an
asymptomatic individual. At risk individuals should sub-
mit themselves for testing when required to make per-
sonal decisions regarding conception, financial matters
and career planning. Testing includes a pre-test inter-
view in which motives for requesting individual know-
ledge of Fahr’s syndrome, possible impact of positive andnegative result and neurological status are assessed [17].
Informed consent (including the possibility of incidental
findings on a CT scan and whether such findings will be
discussed) should be procured and records kept confi-
dential. Individuals with a positive test result need ar-
rangements for long-term follow-up and evaluations.
Testing at risk asymptomatic individual during childhood
Consensus holds that individuals younger than 18 years
who are at risk but asymptomatic should not be tested.
Principal arguments against testing are that such testing
removes individual future autonomy, causes psychological
harm to child by altering self image, disturbing parent
child or sibling-sibling relationships, increases anxiety and
guilt because no treatment is currently available and it is
devoid of any immediate medical benefit [17].
Future perspective
There have been many major advances in our understand-
ing of Fahr’s syndrome, especially in terms of etiology, the
breadth of the disease phenotype and diagnostic methods.
There is no simple solution to this dilemma and contro-
versy. Certainly more qualitative and quantitative data on
the experience of families are needed. Their voice - while
reflecting one aspect of the whole portrait - is crucial and
vital. Secondly, international consensus on guidelines for
care that includes all of the specialties involved in the care
of children and elder people with Fahr’s syndrome is re-
quired. Thirdly, Continuation of the now ongoing dialogue
on this topic by Neurologist, geneticists, Psychiatrist, fam-
ilies, and the appropriate care specialists is mandatory and
welcomed.
Future research should focus on
1. The pathophysiological mechanisms leading to
Bilateral Calcification. Only rare data are available
on the early events leading to bilateral calcification.
2. The development of safe and effective medical
treatments. Currently available drugs are either
poorly effective and/or have bad tolerance.
Conclusion
Idiopathic basal ganglia calcification or Fahr’s syndrome is
a rare neurological disorder that is passed on in families as
an autosomal dominant trait. This disorder is associated
with a variety of other diseases but no specific etiologic
agent has been identified yet. Diagnosis requires the pres-
ence of certain clinical criteria that may confuse the diag-
nosis with other conditions. New treatment modalities
need to be discovered and employed to minimize loss of
functionality associated with the disease. Of even more im-
portance is to emphasize on the significance of genetic
counseling of known at risk parents before conception.
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demonstrate immediate medical benefits in adults or young
individuals. It is of significant use only in adults as it can
help them in decision making in their personal life regard-
ing matters of finance, marriage and career. Screening of
young individuals is considered unnecessary as it can result
in psychological harm without being medically beneficial.
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